1. Home
  2. NBBK vs TBPH Comparison

NBBK vs TBPH Comparison

Compare NBBK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NBBK

NB Bancorp Inc.

HOLD

Current Price

$19.89

Market Cap

889.5M

Sector

N/A

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.40

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBBK
TBPH
Founded
1892
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
889.5M
824.9M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
NBBK
TBPH
Price
$19.89
$16.40
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$23.50
$18.40
AVG Volume (30 Days)
342.8K
282.6K
Earning Date
04-22-2026
05-04-2026
Dividend Yield
1.43%
N/A
EPS Growth
25.23
279.13
EPS
0.36
N/A
Revenue
N/A
$15,386,000.00
Revenue This Year
$45.15
$8.46
Revenue Next Year
$4.18
N/A
P/E Ratio
$55.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.44
$9.10
52 Week High
$22.86
$21.03

Technical Indicators

Market Signals
Indicator
NBBK
TBPH
Relative Strength Index (RSI) 45.25 46.74
Support Level $19.32 $16.14
Resistance Level $20.67 $17.21
Average True Range (ATR) 0.37 0.38
MACD 0.05 -0.07
Stochastic Oscillator 48.59 29.31

Price Performance

Historical Comparison
NBBK
TBPH

About NBBK NB Bancorp Inc.

NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: